Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative ...

(SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe stress-related conditions ... severe ...

This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), has shown ...

Cybin has reported 71% remission in patients with major depressive disorder (MDD) who received two doses of the ... that are ...

One major approach is to learn what ... The role of exposure in treatment of anxiety disorders: A meta-analysis.